Dr Chung Looi is the CEO of Ablatus, which is solving a huge female health issue. Up to 8 in 10 women aged before 50 suffer from uterine fibroids, a market estimated at $4.6Bn. Ablatus offers the potential for incisionless, fertility-preserving, same-day procedure using patented DC-enhanced radiofrequency ablation technology at significantly lower costs. With only 2 FDA-approved solutions amongst competitors valued between $85m-25Bn, and existing UK and US regulatory and reimbursement pathways, Ablatus is raising £2M to offer a better, faster, and cheaper treatment option for millions of women by the end of 2024.  Chung has over 10 years of experience working in biomedical research and med-tech companies. Prior to Ablatus, she led strategic partnerships with life sciences, health insurers, research organisations, and health systems in the US, Asia, and EMEA to bring cutting-edge medical devices from the UK and Denmark to global markets. She holds a DPhil (PhD) in Experimental Psychology from the University of Oxford.